Giant Prolactinoma of Young Onset: A Clue to Diagnosis of MEN-1 Syndrome
Open Access
- 14 August 2018
- journal article
- case report
- Published by Wiley in Case Reports in Endocrinology
- Vol. 2018, 1-6
Abstract
Multiple endocrine neoplasia (MEN) type 1 syndrome is an autosomal dominant disorder caused by germline mutations in MEN1 gene, characterized by tumours in endocrine and nonendocrine organs. Giant prolactinoma is defined as tumours larger than 40mm with very high prolactin secretion. We report two unrelated Sri Lankan patients (8-year-old boy and a 20-year-old female) who presented with giant prolactinomas with mass effects of the tumours. The female patient showed complete response to medical therapy, while the boy developed recurrent resistant prolactinoma needing surgery and radiotherapy. During follow-up, both developed pancreatic neuroendocrine tumours. Genetic analysis revealed that one was heterozygous for a nonsense mutation and other for missense mutation in MEN1 gene. Screening confirmed familial MEN-1 syndrome in their families. High clinical suspicion upon unusual clinical presentation prompted genetic evaluation in these patients and detection of MEN1 gene mutation. Pituitary adenomas in children with MEN-1 syndrome are larger tumours with higher rates of treatment resistance. This report emphasizes importance of screening young patients with giant prolactinoma for MEN-1 syndrome and arranging long-term follow-up for them expecting variable treatment outcomes. Sri Lanka requires further studies to describe the genotypic-phenotypic variability of MEN-1 syndrome in this population.Keywords
Funding Information
- Barts and The London Charity
- UK’s Medical Research Council
- Pfizer
This publication has 17 references indexed in Scilit:
- Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomasPituitary, 2016
- Long-Term Natural Course of Pituitary Tumors in Patients With MEN1: Results From the DutchMEN1 Study Group (DMSG)The Journal of Clinical Endocrinology & Metabolism, 2015
- Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growthEuropean Journal of Endocrinology, 2015
- MEN1 Disease Occurring Before 21 Years Old: A 160-Patient Cohort Study From the Groupe d'étude des Tumeurs EndocrinesThe Journal of Clinical Endocrinology & Metabolism, 2015
- Giant prolactinomas: the therapeutic approachClinical Endocrinology, 2013
- Familial pituitary adenomas – who should be tested for AIP mutations?Clinical Endocrinology, 2012
- Pituitary tumors in patients with MEN1 syndromeClinics, 2012
- Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patientsEuropean Journal of Endocrinology, 2009
- Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the geneHuman Mutation, 2007
- Pituitary Disease in MEN Type 1 (MEN1): Data from the France-Belgium MEN1 Multicenter StudyThe Journal of Clinical Endocrinology & Metabolism, 2002